Give me the script for Detailed internal medicine presentation on viral hepatitis

Reading File

Finding Sources

Searching PubMed

"viral hepatitis" AND management

Now let me read the key sources in parallel — the GI/Liver disease textbook (comprehensive) and Robbins pathology for mechanisms:

Reading File

Excellent content from Robbins. Let me now read more depth on HBV, HCV, HDV, HEV, and the clinical features/management sections:

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

I now have rich content from the textbooks. Let me compile the full, detailed presentation script.---

🎙️ Detailed Internal Medicine Presentation Script: Viral Hepatitis

SLIDE 1 — TITLE SLIDE

"Viral Hepatitis: A Comprehensive Clinical Review" Department of Internal Medicine Grand Rounds

Presenter script:

"Good morning/afternoon, colleagues. Today I'll be presenting a comprehensive review of viral hepatitis — covering all five hepatotropic viruses, their epidemiology, pathophysiology, clinical features, serological diagnosis, and current evidence-based management. This remains one of the most globally significant liver diseases, affecting hundreds of millions of people worldwide."

SLIDE 2 — OVERVIEW & OBJECTIVES

Learning Objectives:

Distinguish the five major hepatitis viruses by virology, transmission, and natural history
Interpret serological markers for acute vs. chronic infection
Apply current treatment guidelines (EASL, AASLD, WHO)
Recognize and manage complications: cirrhosis, HCC, fulminant hepatic failure

Presenter script:

"By the end of this presentation, you should be able to differentiate the hepatitis viruses clinically and serologically, understand when to initiate antiviral therapy, and recognize life-threatening complications. We'll focus particularly on HBV and HCV, which carry the greatest burden of chronic disease."

SLIDE 3 — DEFINITION & TERMINOLOGY

Key Points:

The term hepatitis is applied to:
- (1) Diseases caused by hepatotropic viruses (HAV, HBV, HCV, HDV, HEV) — viruses with specific tropism for the liver
- (2) Patterns of hepatic injury from non-hepatotropic viruses (EBV, CMV, yellow fever), autoimmune reactions, drugs, and toxins
Acute hepatitis: <6 months duration
Chronic hepatitis: Persistence of elevated liver enzymes or hepatic inflammation >6 months

Presenter script:

"It's important to clarify the terminology from the outset. The word 'hepatitis' is applied to two distinct groups. First, diseases caused by hepatotropic viruses — those with specific tropism for the liver. Second, a pattern of hepatic injury caused by non-hepatotropic viruses like EBV and CMV, or by drugs and toxins. Today we focus exclusively on the hepatotropic viruses."

Source: Robbins & Kumar Basic Pathology

SLIDE 4 — COMPARATIVE OVERVIEW TABLE

Feature	HAV	HBV	HCV	HDV	HEV
Genome	ssRNA	dsDNA	ssRNA	ssRNA	ssRNA
Virus family	Picornavirus	Hepadnavirus	Flavivirus	Deltaviridae	Hepeviridae
Transmission	Fecal-oral	Parenteral/sexual/perinatal	Parenteral	Parenteral (coinfection/superinfection with HBV)	Fecal-oral
Incubation	2–6 weeks	4 weeks–6 months	4–26 weeks	3–7 weeks	2–8 weeks
Chronicity	No	Yes (5–10% adults; 90% neonates)	Yes (80–90%)	Yes (if superinfection)	No (except in immunosuppressed)
Fulminant	Rare (0.1%)	Yes	Rare	High (superinfection)	High in pregnancy (20%)

Presenter script:

"This comparative table is your anchor for the entire presentation. Memorize the key distinctions: HAV and HEV are fecal-oral and do not cause chronic hepatitis in immunocompetent individuals. HCV has the highest chronicity rate at 80–90%. HDV is unique — it absolutely requires HBV to replicate. And HEV carries a devastating 20% mortality in pregnant women."

SLIDE 5 — HEPATITIS A VIRUS (HAV)

Virology

Nonenveloped, positive-strand RNA picornavirus (genus: Hepatovirus)
Single serotype → effective vaccine coverage

Epidemiology

Accounts for approximately 25% of acute hepatitis worldwide
Endemic in countries with poor sanitation and healthcare infrastructure
In high-income countries: ~2,800 cases/year in the USA (>95% decline since 1995 vaccine)
Outbreaks: schools, nurseries, food handlers, shellfish consumption (contaminated seawater)

Transmission

Fecal-oral route — contaminated water and food
Shed in stool for 2–3 weeks before and 1 week after onset of jaundice
Bloodborne transmission very rare (transient viremia)

Pathogenesis

HAV itself is NOT cytopathic
Hepatocellular injury mediated by cytotoxic CD8+ T cells (cellular immune response)

Natural History

Self-limited — does not cause chronic hepatitis
Fulminant hepatitis in ~0.1% of cases
No carrier state

Presenter script:

"Hepatitis A is a self-limited illness. The virus itself is not directly cytopathic — the liver damage is immune-mediated, driven by cytotoxic CD8+ T cells. Since 1995, the HAV vaccine has reduced rates in the United States by more than 95%. Importantly, HAV does not establish a carrier state and does not cause chronic hepatitis."

Source: Robbins & Kumar Basic Pathology

SLIDE 6 — HAV: SEROLOGY & DIAGNOSIS

Serological Markers:

Marker	Significance
IgM anti-HAV	Appears at onset of symptoms → reliable marker of acute infection; declines over months
IgG anti-HAV	Follows IgM; persists for years → lifelong immunity

Presenter script:

"The diagnostic key for HAV is IgM anti-HAV, which appears at symptom onset and is your go-to marker for acute infection. IgG anti-HAV follows and confers lifelong immunity. Fecal viral shedding ends as the IgM titer rises — so by the time your patient presents to clinic with jaundice, they are typically no longer contagious."

SLIDE 7 — HAV: MANAGEMENT & PREVENTION

Management:

Primarily supportive (hydration, rest, symptom management)
Avoid hepatotoxic drugs and alcohol
No specific antiviral therapy
Hospitalize if signs of fulminant hepatitis: coagulopathy, encephalopathy

Prevention:

Vaccine (available since 1995): 2-dose series, >95% efficacy
Post-exposure prophylaxis: HAV vaccine within 2 weeks of exposure; Immune globulin for immunocompromised
Improved sanitation, hand hygiene

Presenter script:

"Management of HAV is supportive. No antiviral exists. Your clinical role is to identify the rare patient who is progressing toward fulminant hepatic failure — screen for encephalopathy, coagulopathy, and rising bilirubin. Prevention is paramount. The HAV vaccine is one of medicine's great success stories."

SLIDE 8 — HEPATITIS B VIRUS (HBV)

Virology

Partially double-stranded DNA virus — Hepadnaviridae family
Contains: HBsAg (surface), HBcAg (core), HBeAg (e-antigen, marker of replication)
Encodes a reverse transcriptase — key drug target

Epidemiology

~300 million chronic carriers worldwide
Estimated 820,000 deaths/year from cirrhosis and HCC
High endemicity: Sub-Saharan Africa, Southeast Asia, Pacific Islands
Primary route in endemic areas: perinatal (vertical) transmission
Primary route in low-endemicity: parenteral, sexual

Transmission Routes

Perinatal (most important in endemic areas — SE Asia, Africa)
Parenteral — IV drug use, needlestick, blood products
Sexual contact
Horizontal (household contacts in early childhood)

Presenter script:

"Hepatitis B is a global pandemic. Over 300 million people live with chronic HBV infection. The route of transmission determines the likelihood of chronicity. Perinatal transmission — the most important perpetuator of the worldwide epidemic — results in a 90% rate of chronic infection because the neonatal immune system cannot clear the virus. In contrast, adult exposure results in only 5–10% chronicity."

Source: Robbins & Kumar Basic Pathology; Sleisenger & Fordtran's

SLIDE 9 — HBV: VIROLOGY & REPLICATION

Key Viral Proteins:

HBsAg (Hepatitis B surface antigen): Marker of infection; persists in chronic carriers
HBcAg (Core antigen): Found only in hepatocytes; not detectable in serum
HBeAg (e-antigen): Soluble, secreted protein; marker of active viral replication & high infectivity
HBV DNA: Direct measure of viral load
Anti-HBs: Antibody to HBsAg → marker of immunity/recovery
Anti-HBc IgM: Marker of acute infection
Anti-HBc IgG: Marker of past or chronic infection

Ground-Glass Hepatocytes (Histopathology)

Characteristic finding in chronic HBV
Caused by accumulation of HBsAg in the ER
Appear as finely granular, pale eosinophilic cytoplasm on H&E staining
Confirmed by immunohistochemistry for HBsAg

Presenter script:

"Understanding HBV serology is fundamental to internal medicine. HBsAg is your screening marker. HBeAg and HBV DNA tell you about replication activity. Anti-HBc IgM diagnoses acute infection even in the 'window period' when HBsAg may have cleared but anti-HBs hasn't yet appeared. On biopsy, the pathognomonic finding in chronic HBV is ground-glass hepatocytes — pale, finely granular cytoplasm caused by HBsAg accumulation, confirmed with immunostain."

SLIDE 10 — HBV: SEROLOGICAL PATTERNS

Clinical Scenario	HBsAg	Anti-HBs	Anti-HBc IgM	Anti-HBc IgG	HBeAg	HBV DNA
Acute HBV	+	–	+	–	+	+
Window period	–	–	+	+	–	Low
Resolved infection	–	+	–	+	–	–
Chronic HBV (active)	+	–	–	+	+	High
Chronic HBV (inactive carrier)	+	–	–	+	–	Low
Vaccinated	–	+	–	–	–	–

Presenter script:

"This table is essential for clinical practice. The 'window period' is the diagnostic pitfall — HBsAg has cleared but anti-HBs hasn't appeared yet. Anti-HBc IgM saves you here. Notice that vaccination produces only anti-HBs without anti-HBc — this distinguishes immunity from vaccination versus natural infection."

SLIDE 11 — HBV: NATURAL HISTORY & PHASES OF CHRONIC INFECTION

Five Phases of Chronic HBV:

Immune Tolerant Phase: High HBV DNA, HBeAg positive, normal ALT, minimal liver inflammation → common in perinatally infected patients
Immune Active (Clearance) Phase: HBV DNA high, HBeAg positive, elevated ALT, active necroinflammation
Immune Control (Inactive Carrier) Phase: Low HBV DNA, HBeAg negative/anti-HBe positive, normal ALT
HBeAg-negative Chronic Hepatitis: HBV DNA elevated (>2000 IU/mL), HBeAg negative (mutant virus), elevated ALT — clinically significant
HBsAg Clearance ("functional cure"): HBsAg seroconversion — rare, associated with improved outcomes

Outcomes of Chronic HBV:

Nonprogressive chronic hepatitis
Progressive chronic disease → cirrhosis (in ~20% over 20 years)
Fulminant hepatitis with massive necrosis
HCC (200× increased risk compared to non-infected)

Presenter script:

"The natural history of chronic HBV is dynamic. Patients cycle through these phases, sometimes spontaneously. The clinically dangerous scenarios are the immune active phase and HBeAg-negative chronic hepatitis — both are associated with significant liver injury and risk of progression to cirrhosis and hepatocellular carcinoma."

SLIDE 12 — HBV: TREATMENT INDICATIONS & AGENTS

When to Treat (EASL 2017 / AASLD 2018):

HBV DNA >2,000 IU/mL AND ALT >ULN + moderate necroinflammation or fibrosis
Compensated or decompensated cirrhosis with detectable HBV DNA
HBV DNA >20,000 IU/mL with ALT >2× ULN
HBeAg-positive, high HBV DNA, age >30 years
Family history of HCC or cirrhosis; extrahepatic manifestations

First-Line Antiviral Agents:

Drug	Class	Key Features
Tenofovir disoproxil fumarate (TDF)	Nucleotide analog (NtRTI)	High potency, high barrier to resistance
Tenofovir alafenamide (TAF)	Nucleotide analog	Improved renal/bone safety vs TDF
Entecavir (ETV)	Nucleoside analog (NRTI)	High potency, high barrier to resistance; avoid in lamivudine-experienced
Pegylated IFN-α	Immunomodulator	Finite duration (48 weeks); HBeAg seroconversion possible; not for decompensated cirrhosis

Agents no longer preferred: Lamivudine, adefovir, telbivudine — high resistance rates

Treatment Goal: Suppress HBV DNA to undetectable → reduce liver inflammation, prevent cirrhosis and HCC

Functional cure (HBsAg loss) remains the ultimate goal but is achieved in only ~1% per year on NAs.

Presenter script:

"All major guidelines — EASL, AASLD, APASL, and WHO — converge on tenofovir and entecavir as preferred first-line agents for chronic HBV. They have the highest barrier to resistance. TAF is preferred over TDF in patients with renal impairment or osteoporosis. Pegylated interferon offers the advantage of a finite treatment course and the possibility of immune-mediated HBeAg seroconversion, but cannot be used in decompensated cirrhosis."

Source: Yamada's Textbook of Gastroenterology; Goldman-Cecil Medicine

SLIDE 13 — HEPATITIS C VIRUS (HCV)

Virology

Enveloped, single-stranded RNA virus — Flaviviridae family
Genome encodes a single polyprotein → processed into 10 functional proteins:
- NS3/4A protease: required for polyprotein processing → drug target
- NS5A: essential for viral assembly → drug target
- NS5B RNA polymerase: required for replication → drug target
Low-fidelity RNA polymerase → generates quasispecies → rapid genetic variation
7 major genotypes (Gt1–7), multiple subtypes → treatment selection depends on genotype

Epidemiology

~58 million people with chronic HCV globally (WHO 2023)
Accounts for ~1/3 of liver cancer cases in the United States
Major cause of liver transplantation

Transmission

Primarily parenteral: IV drug use (IDU) — most common in high-income countries
Blood transfusion (now near zero with screening)
Needlestick risk: ~1.8% (vs 0.3% for HIV)
Perinatal: ~5–6% from HCV-positive mothers
Sexual: inefficient; higher risk in HIV-coinfected MSM
One-third of patients have no identifiable risk factor

Presenter script:

"Hepatitis C is the great masquerader of hepatology — 85% of acute infections are completely asymptomatic, yet 80 to 90% progress to chronic hepatitis. The virus's genetic variability is remarkable — low-fidelity RNA polymerase creates quasispecies in every patient. This genetic plasticity is why resistance testing matters before treatment. The good news: we now have the tools to cure virtually everyone."

Source: Robbins & Kumar Basic Pathology

SLIDE 14 — HCV: NATURAL HISTORY

Acute HCV:

Incubation: 4–26 weeks (mean 9 weeks)
85% asymptomatic at the time of acute infection
HCV RNA detectable in blood within 1–3 weeks of exposure
Milder acute illness than HBV; severe acute hepatitis rare

Chronic HCV:

80–90% of acutely infected individuals develop chronic infection
Characteristic: episodic ALT elevations separated by periods of near-normal levels
Cirrhosis in approximately 20% over 20–30 years
Risk factors for progression: older age, male gender, alcohol use, immunosuppression, HBV/HIV coinfection, insulin resistance/metabolic syndrome, obesity, type 2 diabetes
Important: Even patients with normal transaminases and detectable HCV RNA require treatment and monitoring

Outcomes:

Cirrhosis → HCC (HCV accounts for ~1/3 of U.S. liver cancer)
Extrahepatic: cryoglobulinemia, membranoproliferative GN, lymphoma

Presenter script:

"The natural history of HCV underscores why universal testing is so important. The acute infection is silent in 85% of patients. They go undiagnosed for decades, developing cirrhosis and HCC without ever knowing they were infected. This is why the CDC now recommends one-time HCV screening for all adults aged 18–79. Critical point: even patients with normal transaminases who have detectable HCV RNA have ongoing liver damage and need treatment."

SLIDE 15 — HCV: SEROLOGICAL DIAGNOSIS

Test	Role
Anti-HCV antibody	Screening test; detectable ~4–10 weeks after infection; does NOT distinguish active from resolved infection
HCV RNA (qualitative)	Confirms active infection; detectable 1–3 weeks post-exposure; used after positive antibody screen
HCV RNA (quantitative)	Viral load; used to monitor treatment response
HCV genotype	Determines treatment regimen selection
HCV core antigen	Alternative to RNA in resource-limited settings
Liver biopsy / Fibroscan	Assess fibrosis stage (Metavir F0–F4)

Window Period: Anti-HCV may be undetectable for weeks → use HCV RNA if high clinical suspicion.

Presenter script:

"The diagnostic algorithm is sequential: screen with anti-HCV antibody, confirm with HCV RNA. A positive antibody with undetectable RNA means resolved infection — follow with a repeat RNA if recent exposure is suspected. Genotyping is essential before prescribing DAAs, particularly for regimens that are genotype-specific."

SLIDE 16 — HCV: TREATMENT — DIRECT-ACTING ANTIVIRALS (DAAs)

Four Classes of DAAs:

Class	Target	Examples
NS3/4A Protease Inhibitors	Viral protease	Grazoprevir, glecaprevir, voxelaprevir
NS5A Inhibitors	NS5A replication complex	Ledipasvir, velpatasvir, pibrentasvir, elbasvir
NS5B Nucleoside Polymerase Inhibitors	RNA polymerase (active site)	Sofosbuvir
NS5B Non-nucleoside Inhibitors	RNA polymerase (allosteric)	(None currently approved in combination use)

Current Preferred Regimens (without cirrhosis):

Regimen	Genotype	Duration
Sofosbuvir/Velpatasvir (SOF/VEL)	Pan-genotypic (1–6)	12 weeks
Glecaprevir/Pibrentasvir (GLE/PIB)	Pan-genotypic (1–6)	8 weeks (treatment-naïve, no cirrhosis)
Sofosbuvir/Velpatasvir/Voxelaprevir	Pan-genotypic; prior NS5A failure	12 weeks
Ledipasvir/Sofosbuvir	Gt 1, 4, 5, 6	12 weeks
Elbasvir/Grazoprevir	Gt 1a, 1b, 4	12 weeks

SVR12 (Sustained Virological Response at 12 weeks) = functional cure

SVR rates: >95% with modern DAA regimens
SVR reduces risk of liver decompensation, HCC, liver-related mortality, and all-cause mortality

Important Safety Consideration:

Test all patients for HBV before starting DAAs — HBV reactivation has been reported in HBV/HCV co-infected patients during DAA therapy, potentially causing fulminant hepatitis and death

Presenter script:

"The DAA revolution has transformed HCV from a feared chronic disease to a curable condition. Modern pan-genotypic regimens like sofosbuvir-velpatasvir achieve cure rates above 95% in 12 weeks — or even 8 weeks with glecaprevir-pibrentasvir in treatment-naïve patients without cirrhosis. NS5A resistance variants matter for genotype 1a and 3 — consider baseline resistance testing. One critical safety point: always screen for HBV co-infection before starting DAAs, as reactivation can be fatal."

Source: Katzung's Basic and Clinical Pharmacology, 16th Ed.

SLIDE 17 — HEPATITIS D VIRUS (HDV)

Virology

Defective RNA virus — requires HBV (specifically HBsAg) for its envelope
Cannot cause infection independently — absolutely requires HBV co-infection
Small, circular, negative-sense ssRNA genome
Contains only one protein: HDAg (hepatitis D antigen)

Two Clinical Presentations:

Coinfection: HDV + HBV simultaneously
- Generally self-limited; resolves with HBV clearance
- Fulminant hepatitis more common than HBV alone
- Low risk of chronicity
Superinfection: HDV in patient with established chronic HBV
- High risk of severe, rapidly progressive chronic hepatitis
- Cirrhosis accelerated; develops in 70–80%
- Highest risk of fulminant hepatitis
- Higher risk of HCC

Epidemiology

~12–15 million co-infected globally
Endemic in Mediterranean, Middle East, Central Asia, Amazon basin

Diagnosis

Anti-HDV antibody (IgM for acute; IgG for chronic)
HDV RNA — quantitative, confirms active replication

Treatment

Pegylated IFN-α (48 weeks): Only established treatment; response rates poor (~25%)
Bulevirtide (entry inhibitor): Approved in Europe 2020 — new mechanism, promising early data
Ultimately: Treat underlying HBV with NAs; prevent new HBV infection (vaccination) → prevents HDV

Presenter script:

"Hepatitis D is the most severe form of viral hepatitis. Its unique dependency on HBV means that preventing HBV with vaccination completely eliminates the risk of HDV. Superinfection — HDV in someone already chronically infected with HBV — carries particularly poor outcomes, with cirrhosis developing in up to 80%. Treatment options remain limited, though bulevirtide represents a major advance approved in Europe."

SLIDE 18 — HEPATITIS E VIRUS (HEV)

Virology

Non-enveloped, positive-sense ssRNA virus — Hepeviridae family
4 genotypes, 1 serotype
Gt 1 & 2: Infect humans only → epidemic disease (monsoon season, Asia/India)
Gt 3 & 4: Zoonotic — infect humans, swine, chickens, cattle, sheep → sporadic disease in farmers

Transmission

Fecal-oral (contaminated water) — Gt 1 & 2
Zoonotic (undercooked pork/poultry) — Gt 3 & 4

Clinical Features

Usually self-limited in immunocompetent individuals
Pregnant women (3rd trimester): Fulminant hepatic failure — mortality up to 20%
Also associated with: intrauterine fetal death, preterm delivery, neonatal hepatitis (vertical transmission)
Chronic HEV: reported in immunosuppressed patients (solid organ transplant recipients, HIV) with Gt 3

Diagnosis

Anti-HEV IgM: Acute infection
Anti-HEV IgG: Past exposure / immunity
HEV RNA (PCR): Confirms active infection, especially in immunosuppressed

Treatment

Supportive; no proven specific therapy for immunocompetent
Ribavirin ± pegylated IFN-α in chronic HEV (immunosuppressed)
Reduce immunosuppression in transplant recipients

Prevention

Vaccine (HEV 239, Hecolin®): Approved in China (2011)
Avoid contaminated water; cook meat thoroughly

Presenter script:

"Hepatitis E deserves special attention for two reasons. First, its catastrophic impact in pregnancy — acute HEV in the third trimester carries a 20% mortality rate and should be suspected in any pregnant woman returning from or living in endemic areas with acute hepatitis. Second, chronic HEV in immunosuppressed patients — especially solid organ transplant recipients — is an underdiagnosed entity. These patients don't clear the virus, and ribavirin can achieve viral clearance in many."

Source: Sleisenger & Fordtran's GI and Liver Disease

SLIDE 19 — CLINICAL FEATURES OF ACUTE VIRAL HEPATITIS

Prodromal Phase (1–2 weeks before jaundice):

Fatigue, malaise, anorexia, nausea, vomiting
Right upper quadrant discomfort
Low-grade fever
Arthralgias, myalgias (particularly HBV — immune complex mediated)
Urticaria/rash (serum sickness-like — HBV)
Dark urine (bilirubinuria), pale stools (cholestatic phase)

Icteric Phase:

Jaundice — scleral icterus first, then skin
Tender hepatomegaly
Transient splenomegaly in 10–15%
Pruritis if cholestatic component prominent

Recovery Phase:

Jaundice fades, appetite returns
Fatigue may persist weeks to months

Laboratory Findings:

Test	Finding
ALT/AST	Markedly elevated (often >1000 U/L in acute hepatitis A/B); ALT > AST in viral hepatitis
Bilirubin (total + direct)	Elevated
Alkaline phosphatase	Mildly elevated (or normal)
PT/INR	Prolonged in severe disease — best marker of synthetic function
Albumin	Normal in acute; low if chronic (long half-life)
CBC	Leukopenia (especially with EBV)
HBsAg, anti-HAV IgM, anti-HCV	Serology based on clinical suspicion

Presenter script:

"The clinical presentation of acute viral hepatitis follows a predictable pattern. The prodrome — fatigue, anorexia, nausea — precedes jaundice by 1 to 2 weeks. A critical point for clinical practice: the PT/INR is your best early marker of hepatic synthetic function and your most important prognostic indicator. An albumin below 3 g/dL in newly diagnosed hepatitis should raise suspicion of underlying chronic liver disease, given albumin's long half-life."

SLIDE 20 — COMPLICATIONS OF VIRAL HEPATITIS

1. Fulminant Hepatic Failure (Acute Liver Failure)

Definition: Acute liver failure with coagulopathy and hepatic encephalopathy in a patient without pre-existing liver disease
Causes among hepatitis viruses: HAV (rare), HBV (especially reactivation), HDV superinfection, HEV (in pregnancy)
Clinical features: Jaundice, coagulopathy (INR ≥1.5), encephalopathy, cerebral edema → herniation
Management:
- ICU admission; treat encephalopathy (lactulose, rifaximin)
- Correct coagulopathy (FFP, vitamin K)
- Liver transplantation — Status 1 priority; decision within 24 hours; goal transplant within 48–72 hours
- MELD score has prognostic value
Mortality without transplantation: very high (>70% for grade III–IV encephalopathy)

2. Cirrhosis

End-stage fibrosis following years of chronic hepatic inflammation
Complications: portal hypertension, ascites, variceal bleeding, hepatic encephalopathy, hepatorenal syndrome, spontaneous bacterial peritonitis
Decompensation: Child-Pugh B/C or MELD ≥15

3. Hepatocellular Carcinoma (HCC)

HBV: 200× increased risk; can occur even without cirrhosis
HCV: 1/3 of HCC in the USA; typically occurs on background of cirrhosis
Surveillance: Ultrasound ± AFP every 6 months in all at-risk patients
Treatment: Resection, transplantation, ablation, TACE, sorafenib (BCLC staging)

4. Extrahepatic Manifestations (Especially HBV & HCV)

HBV: Polyarteritis nodosa, membranous GN, serum sickness
HCV: Mixed cryoglobulinemia, membranoproliferative GN, non-Hodgkin lymphoma, Sjögren-like syndrome, porphyria cutanea tarda

Presenter script:

"Complications are where morbidity and mortality concentrate. Fulminant hepatic failure is a medical emergency — decisions about liver transplant listing must be made within 24 hours. The MELD score guides prognosis and prioritization. Cirrhosis should trigger your HCC surveillance protocol — ultrasound every 6 months. Remember that HBV can cause HCC even in the absence of cirrhosis, which is why surveillance applies to all HBsAg-positive patients with high-risk features regardless of fibrosis stage."

Source: Goldman-Cecil Medicine; Robbins & Kumar; Sleisenger & Fordtran's

SLIDE 21 — SPECIAL POPULATIONS

1. HBV in Pregnancy

Universal HBV screening of all pregnant women is recommended
Most mother-to-infant transmission occurs at delivery (not in utero)
Maternal infectivity proportional to viral load; HBeAg-positive mothers have highest transmission rates
Prevention of vertical transmission:
- Neonatal HBsAg vaccine + HBIG within 12 hours of birth → 85–95% protection
- Tenofovir in final trimester if HBV DNA >200,000 IU/mL to further reduce transmission
Breastfeeding: allowed if infant receives vaccination + HBIG

2. HEV in Pregnancy

Acute HEV in 3rd trimester → FHF, mortality up to 20%
Intrauterine fetal death, preterm delivery, neonatal hepatitis (vertical transmission)
No known therapy prevents vertical transmission
Avoid travel to endemic areas during monsoon season

3. HIV/HBV or HIV/HCV Coinfection

Accelerated progression to cirrhosis and HCC
Use antiretrovirals active against both viruses (tenofovir + emtricitabine in the HIV regimen covers HBV)
DAAs for HCV can be used safely in HIV-positive patients (check drug–drug interactions)

4. Immunosuppressed Patients / Biologic Therapy

HBV reactivation risk with rituximab, corticosteroids, TNF-α inhibitors, chemotherapy
Prophylactic entecavir or tenofovir before immunosuppression in all HBsAg+ patients
Occult HBV (HBsAg–/anti-HBc+) also at risk — monitor HBV DNA

Presenter script:

"Special populations deserve dedicated attention. HBV in pregnancy is the world's single most important perpetuator of chronic HBV infection. Combination of neonatal vaccine plus HBIG at birth reduces vertical transmission by 85 to 95%. For high viral load mothers — above 200,000 IU/mL — adding tenofovir in the third trimester reduces it further. On the opposite end, HEV in pregnancy is a true obstetric emergency with 20% mortality in the third trimester."

SLIDE 22 — PREVENTION SUMMARY

Virus	Vaccine Available	Post-Exposure Prophylaxis	Other Prevention
HAV	Yes (since 1995)	HAV vaccine within 2 weeks; IG for immunocompromised	Sanitation, hand hygiene
HBV	Yes (since 1982)	HBIG + vaccine within 24h (needlestick/sexual); neonatal vaccine + HBIG	Universal infant vaccination; safe sex; harm reduction
HCV	No vaccine	No effective PEP	Harm reduction (clean needles); blood product screening; sexual risk counseling
HDV	Prevented by HBV vaccination	HBV vaccination prevents HDV	As above for HBV
HEV	Yes (HEV 239, China only)	None established	Safe water; cook pork; avoid endemic areas in pregnancy

Presenter script:

"Vaccination is the cornerstone of prevention for HAV, HBV — and by extension HDV. The HBV vaccine program, introduced universally in many countries, is one of the world's most effective anti-cancer vaccines — it prevents HCC. There is currently no vaccine or post-exposure prophylaxis for HCV, making harm reduction and universal screening the primary public health strategies."

SLIDE 23 — A CLINICAL APPROACH: ALGORITHM

When a patient presents with elevated liver enzymes or jaundice:

History: Exposures (travel, shellfish, IV drugs, sexual contacts, tattoos, blood transfusion, medications), alcohol, family history, HIV status, pregnancy
Physical exam: Jaundice, hepatomegaly, splenomegaly, spider nevi, asterixis (encephalopathy)
Initial labs:
- LFTs: ALT, AST, ALP, GGT, total + direct bilirubin, albumin
- PT/INR (synthetic function)
- CBC, BMP
Viral serology panel (simultaneously):
- Anti-HAV IgM
- HBsAg, Anti-HBc IgM, HBV DNA
- Anti-HCV → if positive, HCV RNA + genotype
- Anti-HDV (if HBsAg positive)
- Anti-HEV IgM (if endemic exposure or pregnancy)
Assess severity:
- INR >1.5 + encephalopathy → Acute Liver Failure protocol
- Consider liver biopsy if uncertain diagnosis
Management: Targeted per etiology + supportive care

Presenter script:

"In clinical practice, you'll receive a patient with 'elevated liver enzymes' — your diagnostic algorithm must be systematic. Run all the serologies simultaneously rather than sequentially to avoid delay. The PT/INR is your most critical acute prognostic tool. An INR above 1.5 with any mental status change means you need to immediately consider acute liver failure management and transplant evaluation."

SLIDE 24 — KEY TAKEAWAYS & SUMMARY

HAV & HEV: Fecal-oral, self-limited (except HEV in pregnancy), no chronic infection in immunocompetent
HBV: DNA virus, 300M chronic carriers, perinatal transmission causes 90% chronicity; treat with tenofovir or entecavir; vaccine prevents both HBV and HDV
HCV: RNA virus, 80–90% chronicity, 95%+ cure with 8–12 weeks of DAAs (sofosbuvir-based); no vaccine
HDV: Defective virus requiring HBV; superinfection carries worst prognosis; HBV vaccination is ultimate prevention
HEV: Particularly dangerous in pregnancy (20% FHF mortality); chronic in immunosuppressed
Complications: Fulminant failure (transplant emergency), cirrhosis, HCC — surveillance with US ± AFP q6 months
Screen everyone: CDC recommends universal HCV screening (age 18–79) and HBsAg testing in high-risk groups

Presenter script:

"To summarize: viral hepatitis remains one of the most clinically impactful infectious diseases globally. The field has been transformed — HCV is now curable, HBV can be suppressed indefinitely, and our serological tools allow precise diagnosis. Your role as internists is to screen proactively, diagnose accurately, initiate timely antiviral therapy, monitor for complications, and prevent transmission. Thank you."

SLIDE 25 — REFERENCES

Robbins & Kumar Basic Pathology (10th Ed.) — Viral Hepatitis, Chapter 14
Sleisenger & Fordtran's Gastrointestinal and Liver Disease — Chapters 73, 82
Yamada's Textbook of Gastroenterology (7th Ed.) — Table 87.5 (CHB Guidelines)
Katzung's Basic and Clinical Pharmacology (16th Ed.) — Direct-Acting Antivirals for HCV
Goldman-Cecil Medicine — Antivirals for Hepatitis B
EASL Clinical Practice Guidelines: HBV (2017)
AASLD Guidance on Chronic Hepatitis B (2018)
WHO Guidelines on Hepatitis B & C (2015/2018)

PRESENTATION TIPS

Total time: ~45–60 minutes (teaching session) or 20–25 minutes (grand rounds)
Audience engagement: Use the serology table (Slide 10) as a case-based quiz
Case scenarios to consider inserting:
- 28-year-old IV drug user: anti-HCV+, HCV RNA+, Gt 1a → initiating DAA therapy
- Pregnant woman from India at 32 weeks with jaundice + coagulopathy → Acute HEV
- HBsAg+ patient starting rituximab for lymphoma → prophylactic entecavir
- 45-year-old with HBsAg+, ALT 120, HBV DNA 450,000 IU/mL, HBeAg+ → treat with TDF or ETV

I meant give me the JavaScript to run to generate a ppt

Reading File

Good. Now let me build the full JavaScript and run it:

Running Command

ls -la /home/daytona/workspace/ 2>/dev/null || mkdir -p /home/daytona/workspace

Running Command

mkdir -p /home/daytona/workspace/viral-hepatitis-ppt && ls /home/daytona/workspace/viral-hepatitis-ppt

Writing File

~/viral-hepatitis-ppt/generate.js

const pptxgen = require("pptxgenjs");

const pres = new pptxgen();
pres.layout = "LAYOUT_16x9";
pres.author = "Internal Medicine";
pres.title = "Viral Hepatitis – Comprehensive Clinical Review";

// ─────────────────────────────────────────────
// THEME
// ─────────────────────────────────────────────
const C = {
  navy:    "0D2B4E",  // dominant dark bg
  teal:    "0E7C86",  // accent / section headers
  gold:    "E8A020",  // highlight
  white:   "FFFFFF",
  offWhite:"F0F4F8",
  lt:      "B8D4E0",  // light text on dark
  danger:  "C0392B",
  safe:    "1E8449",
  gray:    "4A5568",
  tableH:  "0E7C86",
  tableR1: "EAF4F6",
  tableR2: "FFFFFF",
};

const FONT  = "Calibri";
const FONT2 = "Calibri";

// ─────────────────────────────────────────────
// HELPERS
// ─────────────────────────────────────────────
function darkSlide(slide) {
  slide.background = { color: C.navy };
}
function addHeader(slide, title, subtitle) {
  // top teal bar
  slide.addShape(pres.shapes.RECTANGLE, { x: 0, y: 0, w: 10, h: 0.72, fill: { color: C.teal }, line: { color: C.teal } });
  slide.addText(title.toUpperCase(), {
    x: 0.35, y: 0, w: 9.3, h: 0.72,
    fontSize: 17, bold: true, color: C.white, fontFace: FONT,
    valign: "middle", charSpacing: 1.5, margin: 0,
  });
  if (subtitle) {
    slide.addShape(pres.shapes.RECTANGLE, { x: 0, y: 0.72, w: 10, h: 0.28, fill: { color: C.navy }, line: { color: C.navy } });
    slide.addText(subtitle, {
      x: 0.35, y: 0.72, w: 9.3, h: 0.28,
      fontSize: 10, italic: true, color: C.lt, fontFace: FONT, valign: "middle", margin: 0,
    });
  }
}
function addFooter(slide, text) {
  slide.addShape(pres.shapes.RECTANGLE, { x: 0, y: 5.4, w: 10, h: 0.22, fill: { color: C.teal }, line: { color: C.teal } });
  slide.addText(text, {
    x: 0.2, y: 5.4, w: 9.6, h: 0.22,
    fontSize: 7.5, color: C.white, fontFace: FONT, valign: "middle", margin: 0,
  });
}
function bodyY() { return 1.08; }
function bodyH() { return 4.25; }

function bullets(slide, items, opts = {}) {
  const {
    x = 0.4, y = bodyY(), w = 9.2, h = bodyH(),
    fs = 13.5, color = C.offWhite, indent = 0.3,
    level2items = [],
  } = opts;

  const textArr = [];
  items.forEach((item, i) => {
    const isLast = (i === items.length - 1) && level2items.length === 0;
    textArr.push({
      text: item,
      options: {
        bullet: { code: "25CF", color: C.gold },
        indentLevel: 0,
        breakLine: !isLast,
        fontSize: fs,
        color,
        fontFace: FONT,
        paraSpaceAfter: 4,
      },
    });
  });
  level2items.forEach((item, i) => {
    const isLast = i === level2items.length - 1;
    textArr.push({
      text: item,
      options: {
        bullet: { code: "2013", color: C.lt },
        indentLevel: 1,
        breakLine: !isLast,
        fontSize: fs - 1.5,
        color: C.lt,
        fontFace: FONT,
        paraSpaceAfter: 3,
      },
    });
  });
  slide.addText(textArr, { x, y, w, h, valign: "top" });
}

function twoColBullets(slide, leftTitle, leftItems, rightTitle, rightItems, opts = {}) {
  const { y = bodyY(), h = bodyH(), fs = 12.5 } = opts;
  const colW = 4.5;
  // Left column header
  slide.addShape(pres.shapes.RECTANGLE, { x: 0.3, y: y - 0.05, w: colW, h: 0.32, fill: { color: C.teal }, line: { color: C.teal } });
  slide.addText(leftTitle, { x: 0.3, y: y - 0.05, w: colW, h: 0.32, fontSize: 11, bold: true, color: C.white, fontFace: FONT, valign: "middle", margin: 4 });
  // Right column header
  slide.addShape(pres.shapes.RECTANGLE, { x: 5.2, y: y - 0.05, w: colW, h: 0.32, fill: { color: C.gold }, line: { color: C.gold } });
  slide.addText(rightTitle, { x: 5.2, y: y - 0.05, w: colW, h: 0.32, fontSize: 11, bold: true, color: C.navy, fontFace: FONT, valign: "middle", margin: 4 });

  const makeArr = (items) => items.map((item, i) => ({
    text: item,
    options: { bullet: { code: "25CF", color: C.gold }, breakLine: i < items.length - 1, fontSize: fs, color: C.offWhite, fontFace: FONT, paraSpaceAfter: 4 },
  }));
  slide.addText(makeArr(leftItems),  { x: 0.3,  y: y + 0.32, w: colW, h: h - 0.32, valign: "top" });
  slide.addText(makeArr(rightItems), { x: 5.2,  y: y + 0.32, w: colW, h: h - 0.32, valign: "top" });
}

// Simple table helper
function addTable(slide, headers, rows, opts = {}) {
  const { x = 0.3, y = bodyY(), w = 9.4, fontSize = 10.5 } = opts;
  const colW = w / headers.length;
  const tableData = [];
  tableData.push(headers.map(h => ({
    text: h,
    options: { bold: true, color: C.white, fill: C.tableH, fontSize, fontFace: FONT, align: "center", valign: "middle" },
  })));
  rows.forEach((row, ri) => {
    tableData.push(row.map((cell, ci) => ({
      text: cell,
      options: {
        fontSize: fontSize - 0.5,
        color: C.gray,
        fill: ri % 2 === 0 ? C.tableR1 : C.tableR2,
        fontFace: FONT,
        align: ci === 0 ? "left" : "center",
        valign: "middle",
      },
    })));
  });
  slide.addTable(tableData, {
    x, y, w,
    colW: Array(headers.length).fill(colW),
    border: { type: "solid", color: "D0DDE5", pt: 0.5 },
    rowH: 0.34,
  });
}

// ═══════════════════════════════════════════════
// SLIDE 1 – TITLE
// ═══════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkSlide(s);
  // left accent stripe
  s.addShape(pres.shapes.RECTANGLE, { x: 0, y: 0, w: 0.18, h: 5.625, fill: { color: C.teal }, line: { color: C.teal } });
  // gold accent
  s.addShape(pres.shapes.RECTANGLE, { x: 0.18, y: 0, w: 0.08, h: 5.625, fill: { color: C.gold }, line: { color: C.gold } });
  // main title
  s.addText("VIRAL HEPATITIS", {
    x: 0.55, y: 1.2, w: 9.1, h: 1.1,
    fontSize: 42, bold: true, color: C.white, fontFace: FONT, charSpacing: 3,
  });
  s.addText("A Comprehensive Clinical Review", {
    x: 0.55, y: 2.35, w: 9.1, h: 0.55,
    fontSize: 20, italic: true, color: C.lt, fontFace: FONT,
  });
  s.addShape(pres.shapes.RECTANGLE, { x: 0.55, y: 3.0, w: 3.8, h: 0.05, fill: { color: C.gold }, line: { color: C.gold } });
  s.addText("Department of Internal Medicine  |  Grand Rounds", {
    x: 0.55, y: 3.15, w: 9.1, h: 0.4,
    fontSize: 12, color: C.lt, fontFace: FONT,
  });
  s.addText("HAV  •  HBV  •  HCV  •  HDV  •  HEV", {
    x: 0.55, y: 3.65, w: 9.1, h: 0.4,
    fontSize: 13, color: C.gold, fontFace: FONT, bold: true,
  });
}

// ═══════════════════════════════════════════════
// SLIDE 2 – LEARNING OBJECTIVES
// ═══════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkSlide(s);
  addHeader(s, "Learning Objectives");
  const items = [
    "Classify the five hepatotropic viruses by virology, transmission, and natural history",
    "Interpret serological markers for acute vs. chronic infection",
    "Apply current treatment guidelines (EASL 2017, AASLD 2018, WHO)",
    "Initiate antiviral therapy at the right time with the right agent",
    "Recognize and manage complications: cirrhosis, HCC, and fulminant hepatic failure",
    "Counsel special populations: pregnancy, immunosuppressed, HIV co-infection",
  ];
  bullets(s, items, { fs: 14 });
  addFooter(s, "Viral Hepatitis – Internal Medicine Grand Rounds");
}

// ═══════════════════════════════════════════════
// SLIDE 3 – OVERVIEW: COMPARATIVE TABLE
// ═══════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkSlide(s);
  addHeader(s, "Overview: The Five Hepatotropic Viruses");
  addTable(s,
    ["Feature", "HAV", "HBV", "HCV", "HDV", "HEV"],
    [
      ["Genome",         "ssRNA", "dsDNA (partial)", "ssRNA", "ssRNA (defective)", "ssRNA"],
      ["Family",         "Picornavirus", "Hepadnavirus", "Flavivirus", "Deltaviridae", "Hepeviridae"],
      ["Transmission",   "Fecal-oral", "Parenteral / Perinatal / Sexual", "Parenteral (IDU #1)", "Parenteral (needs HBV)", "Fecal-oral / Zoonotic"],
      ["Incubation",     "2–6 wks", "4 wks–6 mo", "4–26 wks (mean 9)", "3–7 wks", "2–8 wks"],
      ["Chronicity",     "None", "5–10% (adults)\n90% (neonates)", "80–90%", "Yes (superinfection)", "None (except immunosuppressed)"],
      ["Fulminant risk", "Rare (0.1%)", "Yes", "Rare", "High (superinfection)", "20% in pregnancy (3rd trimester)"],
      ["Vaccine",        "Yes (1995)", "Yes (1982)", "No", "Prevented by HBV vax", "Yes (China only)"],
    ],
    { y: 1.05, fontSize: 10 }
  );
  addFooter(s, "Viral Hepatitis – Internal Medicine Grand Rounds");
}

// ═══════════════════════════════════════════════
// SLIDE 4 – HEPATITIS A
// ═══════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkSlide(s);
  addHeader(s, "Hepatitis A Virus (HAV)", "Picornavirus · Fecal-oral · Self-limited");
  twoColBullets(s,
    "Virology & Epidemiology",
    [
      "Nonenveloped positive-strand RNA picornavirus (genus Hepatovirus)",
      "Single serotype → effective vaccine coverage",
      "~25% of acute hepatitis worldwide",
      "Endemic in regions with poor sanitation",
      ">95% decline in USA since 1995 vaccine (~2,800 cases/yr)",
      "Outbreaks: schools, food handlers, shellfish",
    ],
    "Pathogenesis & Natural History",
    [
      "Spread via fecal-oral route; shed in stool 2–3 wks before jaundice",
      "Viremia transient → no blood screening required",
      "HAV is NOT directly cytopathic",
      "Hepatocyte injury mediated by CD8+ cytotoxic T cells",
      "Self-limited — DOES NOT cause chronic hepatitis",
      "No carrier state; fulminant hepatitis in only 0.1%",
    ]
  );
  addFooter(s, "Source: Robbins & Kumar Basic Pathology");
}

// ═══════════════════════════════════════════════
// SLIDE 5 – HAV SEROLOGY & MANAGEMENT
// ═══════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkSlide(s);
  addHeader(s, "HAV: Serology, Management & Prevention");

  addTable(s,
    ["Marker", "Significance", "When Detectable"],
    [
      ["IgM anti-HAV", "ACUTE infection marker — diagnostic cornerstone", "At symptom onset; fades in months"],
      ["IgG anti-HAV", "Past infection / immunity", "Follows IgM; persists lifelong"],
    ],
    { y: 1.1, w: 9.4, fontSize: 11 }
  );

  // Management box
  s.addShape(pres.shapes.RECTANGLE, { x: 0.3, y: 2.3, w: 4.5, h: 1.55, fill: { color: C.teal }, line: { color: C.teal }, rectRadius: 0.08 });
  s.addText("Management", { x: 0.3, y: 2.3, w: 4.5, h: 0.35, fontSize: 12, bold: true, color: C.white, fontFace: FONT, align: "center", valign: "middle", margin: 0 });
  s.addText([
    { text: "• Supportive care (hydration, rest)\n", options: {} },
    { text: "• Avoid alcohol and hepatotoxic drugs\n", options: {} },
    { text: "• No specific antiviral therapy\n", options: {} },
    { text: "• ICU if fulminant (coagulopathy, encephalopathy)", options: {} },
  ], { x: 0.4, y: 2.65, w: 4.3, h: 1.1, fontSize: 11, color: C.white, fontFace: FONT });

  // Prevention box
  s.addShape(pres.shapes.RECTANGLE, { x: 5.2, y: 2.3, w: 4.5, h: 1.55, fill: { color: C.gold }, line: { color: C.gold }, rectRadius: 0.08 });
  s.addText("Prevention", { x: 5.2, y: 2.3, w: 4.5, h: 0.35, fontSize: 12, bold: true, color: C.navy, fontFace: FONT, align: "center", valign: "middle", margin: 0 });
  s.addText([
    { text: "• HAV vaccine (2-dose series, >95% efficacy)\n", options: {} },
    { text: "• PEP: vaccine within 2 weeks of exposure\n", options: {} },
    { text: "• IG for immunocompromised contacts\n", options: {} },
    { text: "• Safe water, hand hygiene, sanitation", options: {} },
  ], { x: 5.3, y: 2.65, w: 4.3, h: 1.1, fontSize: 11, color: C.navy, fontFace: FONT });

  s.addText("⚠  Screen for fulminant hepatitis: rising INR, encephalopathy — liver transplant evaluation if ALF criteria met", {
    x: 0.3, y: 4.05, w: 9.4, h: 0.45,
    fontSize: 11, color: C.gold, fontFace: FONT, bold: true,
    fill: { color: "1A2E3F" }, margin: 6,
  });
  addFooter(s, "Viral Hepatitis – Internal Medicine Grand Rounds");
}

// ═══════════════════════════════════════════════
// SLIDE 6 – HBV VIROLOGY & EPIDEMIOLOGY
// ═══════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkSlide(s);
  addHeader(s, "Hepatitis B Virus (HBV)", "Hepadnavirus · Partially dsDNA · 300 million chronic carriers worldwide");
  twoColBullets(s,
    "Virology",
    [
      "Partially double-stranded DNA virus — Hepadnaviridae",
      "Encodes a reverse transcriptase → key drug target",
      "Key antigens: HBsAg (surface), HBcAg (core, intrahepatic only), HBeAg (replication marker)",
      "Ground-glass hepatocytes: HBsAg accumulation in ER — pathognomonic on biopsy",
    ],
    "Epidemiology & Transmission",
    [
      "~300 million chronic carriers; 820,000 deaths/yr (cirrhosis + HCC)",
      "High endemicity: Sub-Saharan Africa, SE Asia, Pacific Islands",
      "Route determines chronicity: perinatal → 90%; adult → 5–10%",
      "Perinatal (most important in endemic areas — majority of chronic cases)",
      "Parenteral: IDU, needlestick, blood products",
      "Sexual contact; household horizontal transmission",
    ]
  );
  addFooter(s, "Source: Robbins & Kumar Basic Pathology");
}

// ═══════════════════════════════════════════════
// SLIDE 7 – HBV SEROLOGY
// ═══════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkSlide(s);
  addHeader(s, "HBV: Serological Markers & Interpretation");
  addTable(s,
    ["Clinical Scenario", "HBsAg", "Anti-HBs", "Anti-HBc IgM", "Anti-HBc IgG", "HBeAg", "HBV DNA"],
    [
      ["Acute HBV",              "+", "–", "+ (diagnostic)", "–", "+", "High"],
      ["Window period",          "–", "–", "+", "+", "–", "Low"],
      ["Resolved infection",     "–", "+", "–", "+", "–", "–"],
      ["Chronic HBV (active)",   "+", "–", "–", "+", "+", "High"],
      ["Inactive carrier",       "+", "–", "–", "+", "–", "Low/<2000"],
      ["Vaccinated",             "–", "+ (only)", "–", "–", "–", "–"],
    ],
    { y: 1.1, fontSize: 9.5 }
  );
  s.addText("KEY: Window period — HBsAg cleared, Anti-HBs not yet present → Anti-HBc IgM saves the diagnosis!", {
    x: 0.3, y: 4.7, w: 9.4, h: 0.4,
    fontSize: 11, color: C.gold, bold: true, fontFace: FONT,
    fill: { color: "1A2E3F" }, margin: 6,
  });
  addFooter(s, "Viral Hepatitis – Internal Medicine Grand Rounds");
}

// ═══════════════════════════════════════════════
// SLIDE 8 – HBV NATURAL HISTORY
// ═══════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkSlide(s);
  addHeader(s, "HBV: Natural History & Phases of Chronic Infection");
  const phases = [
    ["1. Immune Tolerant", "High HBV DNA, HBeAg+, normal ALT, minimal inflammation → common in perinatally infected; do NOT treat"],
    ["2. Immune Active (HBeAg+)", "High HBV DNA, HBeAg+, elevated ALT, active necroinflammation → TREAT"],
    ["3. Immune Control (Inactive Carrier)", "Low HBV DNA (<2000 IU/mL), HBeAg–/Anti-HBe+, normal ALT → monitor"],
    ["4. HBeAg-negative Chronic Hepatitis", "HBV DNA >2000 IU/mL, HBeAg– (mutant virus), elevated ALT → clinically significant, TREAT"],
    ["5. HBsAg Clearance (Functional Cure)", "HBsAg loss → rare (~1%/yr on NAs) — best outcome"],
  ];
  const textArr = [];
  phases.forEach(([title, detail], i) => {
    textArr.push({ text: title + "  ", options: { bold: true, color: C.gold, fontSize: 13, fontFace: FONT, breakLine: false } });
    textArr.push({ text: detail, options: { color: C.offWhite, fontSize: 12, fontFace: FONT, breakLine: i < phases.length - 1, paraSpaceAfter: 5 } });
  });
  s.addText(textArr, { x: 0.4, y: bodyY(), w: 9.2, h: bodyH(), valign: "top" });

  s.addText("Outcomes: Nonprogressive chronic hepatitis → Cirrhosis (~20%, 20–30 yrs) → HCC (200× risk) → Fulminant failure", {
    x: 0.3, y: 4.72, w: 9.4, h: 0.4,
    fontSize: 10.5, color: C.white, fontFace: FONT, bold: true,
    fill: { color: C.danger }, margin: 5,
  });
  addFooter(s, "Viral Hepatitis – Internal Medicine Grand Rounds");
}

// ═══════════════════════════════════════════════
// SLIDE 9 – HBV TREATMENT
// ═══════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkSlide(s);
  addHeader(s, "HBV: Treatment Indications & First-Line Agents");

  // Indications box
  s.addShape(pres.shapes.RECTANGLE, { x: 0.3, y: 1.1, w: 9.4, h: 0.32, fill: { color: C.teal }, line: { color: C.teal } });
  s.addText("TREAT WHEN (EASL 2017 / AASLD 2018):", { x: 0.3, y: 1.1, w: 9.4, h: 0.32, fontSize: 11, bold: true, color: C.white, fontFace: FONT, valign: "middle", margin: 5 });
  s.addText([
    { text: "• HBV DNA >2,000 IU/mL + ALT >ULN + moderate fibrosis/necroinflammation  ", options: { breakLine: false } },
    { text: "• Cirrhosis (compensated or decompensated) + detectable HBV DNA\n", options: { breakLine: true } },
    { text: "• HBV DNA >20,000 IU/mL + ALT >2×ULN  ", options: { breakLine: false } },
    { text: "• HBeAg+, high viral load, age >30 yrs; Family history of HCC or cirrhosis", options: { breakLine: false } },
  ], { x: 0.4, y: 1.42, w: 9.2, h: 0.75, fontSize: 11, color: C.offWhite, fontFace: FONT, valign: "top" });

  addTable(s,
    ["Drug", "Class", "Barrier to Resistance", "Key Notes"],
    [
      ["Tenofovir DF (TDF)", "Nucleotide analog (NtRTI)", "High ✓✓", "Preferred; watch renal & bone density"],
      ["Tenofovir AF (TAF)", "Nucleotide analog (NtRTI)", "High ✓✓", "Better renal/bone safety than TDF"],
      ["Entecavir (ETV)", "Nucleoside analog (NRTI)", "High ✓✓", "Avoid if lamivudine-experienced"],
      ["Peg-IFN α-2a", "Immunomodulator", "N/A (finite course)", "48 wks; HBeAg seroconversion possible; NOT for decompensated cirrhosis"],
      ["Lamivudine / Adefovir / Telbivudine", "NRTIs (older)", "Low ✗", "High resistance — no longer preferred"],
    ],
    { y: 2.22, fontSize: 10 }
  );
  s.addText("Goal: Suppress HBV DNA to undetectable → Halt fibrosis progression → Prevent HCC  |  Functional cure (HBsAg loss) in ~1%/yr on NAs", {
    x: 0.3, y: 4.72, w: 9.4, h: 0.4,
    fontSize: 10, color: C.gold, bold: true, fontFace: FONT,
    fill: { color: "1A2E3F" }, margin: 5,
  });
  addFooter(s, "Source: Yamada's Textbook of Gastroenterology; Goldman-Cecil Medicine");
}

// ═══════════════════════════════════════════════
// SLIDE 10 – HCV VIROLOGY & EPIDEMIOLOGY
// ═══════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkSlide(s);
  addHeader(s, "Hepatitis C Virus (HCV)", "Flavivirus · ssRNA · 80–90% chronicity rate");
  twoColBullets(s,
    "Virology",
    [
      "Enveloped ssRNA virus — Flaviviridae family",
      "Encodes single polyprotein → 10 functional proteins (NS3/4A, NS5A, NS5B)",
      "NS3/4A protease, NS5A, NS5B RNA polymerase → all drug targets",
      "Low-fidelity RNA polymerase → quasispecies + 7 major genotypes",
      "Genotyping mandatory before treatment selection",
    ],
    "Epidemiology & Transmission",
    [
      "~58 million chronic carriers worldwide (WHO 2023)",
      "Accounts for ~1/3 of HCC in the United States",
      "IV drug use: dominant route in high-income countries",
      "Needlestick risk: ~1.8% (vs 0.3% for HIV)",
      "Perinatal: 5–6% from HCV+ mothers",
      "Sexual transmission: low efficiency; higher in HIV+ MSM",
      "1/3 of patients: no identifiable risk factor",
    ]
  );
  addFooter(s, "Source: Robbins & Kumar Basic Pathology");
}

// ═══════════════════════════════════════════════
// SLIDE 11 – HCV NATURAL HISTORY & DIAGNOSIS
// ═══════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkSlide(s);
  addHeader(s, "HCV: Natural History & Diagnosis");

  // Natural history timeline boxes
  const boxes = [
    { label: "Acute HCV", detail: "85% asymptomatic\nIncubation 4–26 wks (mean 9)\nHCV RNA detectable at 1–3 wks\nMild illness; severe acute rare", color: C.teal },
    { label: "Chronic HCV\n(80–90%)", detail: "Episodic ALT elevations\nEven normal ALT ≠ safe\nProgression accelerated by:\nalcohol, obesity, T2DM, HIV/HBV", color: "0E5C65" },
    { label: "Cirrhosis\n(~20%, 20–30 yrs)", detail: "Portal hypertension\nAscites, varices\nHepatic encephalopathy\nHRS, SBP", color: C.danger },
    { label: "HCC", detail: "~1/3 of US liver cancers\nUltrasound ± AFP\nevery 6 months surveillance", color: "6B1A1A" },
  ];
  boxes.forEach((box, i) => {
    const bx = 0.3 + i * 2.4;
    s.addShape(pres.shapes.RECTANGLE, { x: bx, y: 1.12, w: 2.25, h: 2.0, fill: { color: box.color }, line: { color: box.color } });
    s.addText(box.label, { x: bx, y: 1.12, w: 2.25, h: 0.45, fontSize: 11, bold: true, color: C.white, fontFace: FONT, align: "center", valign: "middle", margin: 0 });
    s.addText(box.detail, { x: bx + 0.05, y: 1.57, w: 2.15, h: 1.45, fontSize: 9.5, color: C.white, fontFace: FONT, valign: "top", margin: 4 });
  });
  // Arrow between boxes
  for (let i = 0; i < 3; i++) {
    s.addText("▶", { x: 2.45 + i * 2.4, y: 1.85, w: 0.25, h: 0.35, fontSize: 16, color: C.gold, fontFace: FONT });
  }

  // Diagnosis table
  s.addShape(pres.shapes.RECTANGLE, { x: 0.3, y: 3.25, w: 9.4, h: 0.3, fill: { color: C.teal }, line: { color: C.teal } });
  s.addText("DIAGNOSTIC ALGORITHM", { x: 0.3, y: 3.25, w: 9.4, h: 0.3, fontSize: 11, bold: true, color: C.white, fontFace: FONT, valign: "middle", margin: 5 });
  addTable(s,
    ["Step", "Test", "Purpose"],
    [
      ["1st", "Anti-HCV antibody", "Screening — does NOT distinguish active from resolved infection"],
      ["2nd (if Ab+)", "HCV RNA (qualitative)", "Confirms ACTIVE infection; detectable 1–3 wks after exposure"],
      ["3rd", "HCV RNA (quantitative)", "Baseline viral load; monitors treatment response"],
      ["4th", "HCV Genotype (1–7)", "Guides DAA regimen selection"],
    ],
    { y: 3.55, fontSize: 10.5 }
  );
  addFooter(s, "Source: Robbins & Kumar Basic Pathology");
}

// ═══════════════════════════════════════════════
// SLIDE 12 – HCV TREATMENT: DAAs
// ═══════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkSlide(s);
  addHeader(s, "HCV: Direct-Acting Antivirals (DAAs) — The Cure");

  s.addText("SVR12 (undetectable HCV RNA at 12 weeks post-treatment) = FUNCTIONAL CURE — achieved in >95% with modern DAAs", {
    x: 0.3, y: 1.1, w: 9.4, h: 0.38,
    fontSize: 11.5, color: C.navy, bold: true, fontFace: FONT,
    fill: { color: C.gold }, margin: 6,
  });

  addTable(s,
    ["Regimen", "Class", "Genotype(s)", "Duration", "Notes"],
    [
      ["Sofosbuvir / Velpatasvir", "NS5B + NS5A inhibitor", "Pan-genotypic (1–6)", "12 weeks", "Pan-genotypic first-line"],
      ["Glecaprevir / Pibrentasvir", "NS3/4A + NS5A inhibitor", "Pan-genotypic (1–6)", "8 wks (tx-naïve, no cirrhosis)", "Shortest course option"],
      ["SOF/VEL/Voxelaprevir", "NS5B + NS5A + NS3/4A", "Pan-genotypic; NS5A failures", "12 weeks", "Salvage after NS5A failure"],
      ["Ledipasvir / Sofosbuvir", "NS5A + NS5B inhibitor", "Gt 1, 4, 5, 6", "12 weeks", ""],
      ["Elbasvir / Grazoprevir", "NS5A + NS3/4A inhibitor", "Gt 1a, 1b, 4", "12 weeks", "Check NS5A RAVs for Gt 1a"],
    ],
    { y: 1.52, fontSize: 10 }
  );

  s.addText("⚠ SCREEN FOR HBV before starting DAAs — HBV reactivation in co-infected patients can cause fulminant hepatitis and death (start prophylactic NAs if HBsAg+)", {
    x: 0.3, y: 4.0, w: 9.4, h: 0.45,
    fontSize: 10.5, color: C.white, fontFace: FONT, bold: true,
    fill: { color: C.danger }, margin: 6,
  });

  s.addText("Drug-drug interactions: Check rifampin, anticonvulsants, HIV ARVs, PPIs (reduce ledipasvir absorption)", {
    x: 0.3, y: 4.5, w: 9.4, h: 0.35,
    fontSize: 10.5, color: C.offWhite, fontFace: FONT,
    fill: { color: "1A2E3F" }, margin: 5,
  });
  addFooter(s, "Source: Katzung's Basic and Clinical Pharmacology, 16th Ed.");
}

// ═══════════════════════════════════════════════
// SLIDE 13 – HDV
// ═══════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkSlide(s);
  addHeader(s, "Hepatitis D Virus (HDV)", "Defective RNA virus — requires HBV surface antigen to replicate");
  twoColBullets(s,
    "Virology & Epidemiology",
    [
      "Defective ssRNA virus (Deltaviridae) — cannot infect without HBV",
      "Contains only one protein: HDAg (hepatitis D antigen)",
      "~12–15 million co-infected globally",
      "Endemic: Mediterranean, Middle East, Central Asia, Amazon",
      "Diagnosis: Anti-HDV IgM (acute), IgG (chronic); HDV RNA",
    ],
    "Coinfection vs Superinfection",
    [
      "COINFECTION (HBV + HDV simultaneously): usually self-limited; resolves with HBV; low chronicity; higher fulminant risk than HBV alone",
      "SUPERINFECTION (HDV in chronic HBV): rapid progression; cirrhosis in 70–80%; HIGHEST fulminant hepatitis risk; highest HCC risk",
    ]
  );

  s.addText("Treatment: Peg-IFN-α 48 weeks (poor response ~25%)  |  Bulevirtide (entry inhibitor) — approved EU 2020, promising data", {
    x: 0.3, y: 4.38, w: 9.4, h: 0.38,
    fontSize: 11, color: C.navy, bold: true, fontFace: FONT,
    fill: { color: C.gold }, margin: 6,
  });
  s.addText("PREVENTION: HBV vaccination COMPLETELY prevents HDV infection — the ultimate strategy", {
    x: 0.3, y: 4.8, w: 9.4, h: 0.3,
    fontSize: 10.5, color: C.white, fontFace: FONT, bold: true,
    fill: { color: C.safe }, margin: 5,
  });
  addFooter(s, "Viral Hepatitis – Internal Medicine Grand Rounds");
}

// ═══════════════════════════════════════════════
// SLIDE 14 – HEV
// ═══════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkSlide(s);
  addHeader(s, "Hepatitis E Virus (HEV)", "Hepeviridae · Fecal-oral / Zoonotic · 20% mortality in pregnancy");

  addTable(s,
    ["Feature", "Genotypes 1 & 2", "Genotypes 3 & 4"],
    [
      ["Hosts", "Humans only", "Humans + swine, poultry, cattle, sheep"],
      ["Pattern", "Epidemic (monsoon season, South/Central Asia, India)", "Sporadic (farmers, undercooked meat)"],
      ["Chronicity", "No (immunocompetent)", "Yes — in immunosuppressed (organ transplant, HIV)"],
    ],
    { y: 1.12, fontSize: 11 }
  );

  // Alert box – pregnancy
  s.addShape(pres.shapes.RECTANGLE, { x: 0.3, y: 2.55, w: 9.4, h: 0.85, fill: { color: C.danger }, line: { color: C.danger } });
  s.addText("⚠  OBSTETRIC EMERGENCY: Acute HEV in 3rd trimester → Fulminant Hepatic Failure — mortality UP TO 20%\nAlso: intrauterine fetal death, preterm delivery, neonatal hepatitis (vertical transmission)", {
    x: 0.35, y: 2.55, w: 9.3, h: 0.85,
    fontSize: 12, color: C.white, bold: true, fontFace: FONT, valign: "middle", margin: 5,
  });

  bullets(s, [
    "Immunosuppressed patients (transplant, HIV): Chronic HEV (Gt3) — treat with Ribavirin ± Peg-IFN; reduce immunosuppression",
    "Serology: Anti-HEV IgM (acute), IgG (past); HCV RNA for immunosuppressed (antibody response may be blunted)",
    "Prevention: Hecolin® vaccine (China 2011); safe water supply; cook pork/poultry thoroughly; avoid endemic areas in pregnancy",
  ], { y: 3.5, h: 1.7, fs: 12 });
  addFooter(s, "Source: Sleisenger & Fordtran's GI and Liver Disease");
}

// ═══════════════════════════════════════════════
// SLIDE 15 – CLINICAL FEATURES OF ACUTE HEPATITIS
// ═══════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkSlide(s);
  addHeader(s, "Clinical Features of Acute Viral Hepatitis");

  addTable(s,
    ["Phase", "Symptoms & Signs", "Duration"],
    [
      ["Prodromal", "Fatigue, malaise, anorexia, nausea/vomiting; RUQ discomfort; low-grade fever; arthralgias/myalgias; dark urine (bilirubinuria); pale stools; urticaria/serum sickness (HBV)", "1–2 weeks before jaundice"],
      ["Icteric", "Jaundice (scleral icterus first → skin); tender hepatomegaly; transient splenomegaly (10–15%); pruritis if cholestatic", "Days to weeks"],
      ["Recovery", "Jaundice fades, appetite returns; fatigue may persist weeks to months", "Weeks to months"],
    ],
    { y: 1.12, fontSize: 11 }
  );

  s.addShape(pres.shapes.RECTANGLE, { x: 0.3, y: 3.35, w: 9.4, h: 0.3, fill: { color: C.teal }, line: { color: C.teal } });
  s.addText("KEY LABORATORY FINDINGS:", { x: 0.3, y: 3.35, w: 9.4, h: 0.3, fontSize: 11, bold: true, color: C.white, fontFace: FONT, valign: "middle", margin: 5 });

  addTable(s,
    ["Test", "Expected Finding", "Clinical Significance"],
    [
      ["ALT / AST", "Markedly elevated (often >1000 U/L); ALT > AST", "ALT is more hepatocyte-specific"],
      ["Bilirubin (total + direct)", "Elevated", "Jaundice when total >3 mg/dL"],
      ["PT / INR", "Prolonged in severe disease", "Best acute marker of synthetic function — prognostic!"],
      ["Albumin", "Normal in acute hepatitis (long half-life); Low if chronic", "Low albumin = suspect chronic liver disease"],
      ["ALP", "Mildly elevated or normal", "Marked elevation suggests biliary or infiltrative disease"],
    ],
    { y: 3.68, fontSize: 10 }
  );
  addFooter(s, "Viral Hepatitis – Internal Medicine Grand Rounds");
}

// ═══════════════════════════════════════════════
// SLIDE 16 – COMPLICATIONS
// ═══════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkSlide(s);
  addHeader(s, "Complications of Viral Hepatitis");

  const comps = [
    {
      title: "Fulminant Hepatic Failure (ALF)",
      color: C.danger,
      pts: ["Coagulopathy (INR ≥1.5) + Encephalopathy without prior liver disease", "Causes: HBV reactivation, HDV superinfection, HEV in pregnancy, HAV (rare)", "Emergency: ICU, treat encephalopathy (lactulose, rifaximin), FFP/Vit K", "Liver transplantation: Status 1 priority; list within 24h; transplant within 48–72h"],
    },
    {
      title: "Cirrhosis",
      color: C.teal,
      pts: ["End-stage fibrosis from chronic hepatic inflammation", "Complications: portal HTN, ascites, SBP, varices, HRS, hepatic encephalopathy", "Decompensation: Child-Pugh B/C or MELD ≥15 — consider transplant evaluation"],
    },
    {
      title: "Hepatocellular Carcinoma (HCC)",
      color: "7B5E00",
      pts: ["HBV: 200× risk; can occur WITHOUT cirrhosis!", "HCV: ~1/3 of US liver cancers; almost always on cirrhotic background", "SURVEILLANCE: Liver ultrasound ± AFP every 6 months in all at-risk patients"],
    },
  ];
  comps.forEach((comp, i) => {
    const bx = 0.3 + i * 3.25;
    s.addShape(pres.shapes.RECTANGLE, { x: bx, y: 1.12, w: 3.1, h: 0.36, fill: { color: comp.color }, line: { color: comp.color } });
    s.addText(comp.title, { x: bx, y: 1.12, w: 3.1, h: 0.36, fontSize: 11, bold: true, color: C.white, fontFace: FONT, align: "center", valign: "middle", margin: 0 });
    const arr = comp.pts.map((p, pi) => ({
      text: p,
      options: { bullet: { code: "25CF", color: C.gold }, breakLine: pi < comp.pts.length - 1, fontSize: 10.5, color: C.offWhite, fontFace: FONT, paraSpaceAfter: 4 },
    }));
    s.addText(arr, { x: bx + 0.05, y: 1.52, w: 3.0, h: 2.75, valign: "top" });
  });

  s.addShape(pres.shapes.RECTANGLE, { x: 0.3, y: 4.38, w: 9.4, h: 0.3, fill: { color: C.teal }, line: { color: C.teal } });
  s.addText("Extrahepatic manifestations: HBV → Polyarteritis nodosa, membranous GN, serum sickness   |   HCV → Mixed cryoglobulinemia, MPGN, NHL, porphyria cutanea tarda", {
    x: 0.3, y: 4.38, w: 9.4, h: 0.3, fontSize: 9, color: C.white, fontFace: FONT, valign: "middle", margin: 5,
  });
  addFooter(s, "Source: Goldman-Cecil Medicine; Robbins & Kumar; Sleisenger & Fordtran's");
}

// ═══════════════════════════════════════════════
// SLIDE 17 – SPECIAL POPULATIONS
// ═══════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkSlide(s);
  addHeader(s, "Special Populations");

  const sp = [
    {
      title: "HBV in Pregnancy",
      items: [
        "Universal HBV screening of ALL pregnant women",
        "Most transmission occurs at delivery (neonatal immune system cannot clear virus)",
        "HBeAg+ mothers: highest perinatal transmission rates",
        "Prevention: Neonatal HBsAg vaccine + HBIG within 12h of birth → 85–95% protection",
        "If maternal HBV DNA >200,000 IU/mL: add Tenofovir in 3rd trimester",
        "Breastfeeding: allowed if infant vaccinated + HBIG",
      ],
    },
    {
      title: "HEV in Pregnancy",
      items: [
        "3rd trimester: fulminant hepatic failure — mortality up to 20%",
        "Intrauterine fetal death, preterm delivery, neonatal hepatitis",
        "No therapy prevents vertical transmission",
        "Avoid travel to endemic areas during monsoon season",
      ],
    },
    {
      title: "Immunosuppressed Patients",
      items: [
        "HBV reactivation risk: rituximab, steroids, TNF-α inhibitors, chemotherapy",
        "Prophylactic entecavir/tenofovir before immunosuppression in ALL HBsAg+ patients",
        "Occult HBV (HBsAg–/Anti-HBc+): monitor HBV DNA; consider prophylaxis for high-risk agents",
        "Chronic HEV (Gt 3): treat with ribavirin ± IFN; reduce immunosuppression",
      ],
    },
  ];

  const colW = 3.05;
  sp.forEach((col, i) => {
    const bx = 0.3 + i * 3.23;
    s.addShape(pres.shapes.RECTANGLE, { x: bx, y: 1.12, w: colW, h: 0.34, fill: { color: C.teal }, line: { color: C.teal } });
    s.addText(col.title, { x: bx, y: 1.12, w: colW, h: 0.34, fontSize: 10.5, bold: true, color: C.white, fontFace: FONT, align: "center", valign: "middle", margin: 0 });
    const arr = col.items.map((t, pi) => ({
      text: t,
      options: { bullet: { code: "25CF", color: C.gold }, breakLine: pi < col.items.length - 1, fontSize: 10.5, color: C.offWhite, fontFace: FONT, paraSpaceAfter: 3 },
    }));
    s.addText(arr, { x: bx + 0.05, y: 1.5, w: colW - 0.1, h: 3.6, valign: "top" });
  });
  addFooter(s, "Source: Sleisenger & Fordtran's GI and Liver Disease");
}

// ═══════════════════════════════════════════════
// SLIDE 18 – PREVENTION SUMMARY
// ═══════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkSlide(s);
  addHeader(s, "Prevention Summary");
  addTable(s,
    ["Virus", "Vaccine", "Post-Exposure Prophylaxis", "Other Measures"],
    [
      ["HAV", "Yes — 2-dose (since 1995)", "Vaccine within 2 wks; IG for immunocompromised", "Safe water; hand hygiene; sanitation"],
      ["HBV", "Yes — 3-dose (since 1982)\nUniversal infant vaccination", "HBIG + vaccine within 24h\n(needlestick/sexual/neonatal)", "Safe sex; needle exchange; universal infant vaccination"],
      ["HCV", "NO vaccine available", "No effective PEP", "Harm reduction; needle exchange; blood screening; DAA treatment as prevention"],
      ["HDV", "Prevented by HBV vaccination (no separate vaccine)", "HBV PEP prevents HDV", "Same as HBV prevention"],
      ["HEV", "Yes — Hecolin® (China only)", "None established", "Safe water; fully cook pork/poultry; pregnant women avoid endemic areas"],
    ],
    { y: 1.12, fontSize: 10.5 }
  );
  s.addText("HBV vaccination is one of the world's most effective anti-cancer vaccines — it prevents hepatocellular carcinoma", {
    x: 0.3, y: 4.78, w: 9.4, h: 0.35,
    fontSize: 11, color: C.navy, bold: true, fontFace: FONT,
    fill: { color: C.gold }, margin: 5,
  });
  addFooter(s, "Viral Hepatitis – Internal Medicine Grand Rounds");
}

// ═══════════════════════════════════════════════
// SLIDE 19 – CLINICAL APPROACH ALGORITHM
// ═══════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkSlide(s);
  addHeader(s, "Clinical Approach: Elevated Liver Enzymes / Jaundice");

  const steps = [
    { n: "1", label: "History", detail: "Exposures: travel, shellfish, IDU, sexual contacts, tattoos, blood products; alcohol; medications; family history; pregnancy; HIV status" },
    { n: "2", label: "Exam", detail: "Jaundice, hepatomegaly, splenomegaly, spider nevi, asterixis (encephalopathy = ALF alarm)" },
    { n: "3", label: "Initial Labs", detail: "ALT, AST, ALP, GGT, total + direct bilirubin, albumin, PT/INR, CBC, BMP" },
    { n: "4", label: "Viral Serology\n(run simultaneously)", detail: "Anti-HAV IgM  |  HBsAg, Anti-HBc IgM, HBV DNA  |  Anti-HCV → if+: HCV RNA + genotype  |  Anti-HDV (if HBsAg+)  |  Anti-HEV IgM (endemic exposure / pregnancy)" },
    { n: "5", label: "Assess Severity", detail: "INR >1.5 + encephalopathy → ACUTE LIVER FAILURE protocol; consider transplant listing within 24h" },
    { n: "6", label: "Manage", detail: "Targeted antiviral therapy per etiology + supportive care + specialist referral" },
  ];

  steps.forEach((step, i) => {
    const bx = 0.3;
    const by = 1.12 + i * 0.69;
    s.addShape(pres.shapes.RECTANGLE, { x: bx, y: by, w: 0.55, h: 0.55, fill: { color: C.gold }, line: { color: C.gold } });
    s.addText(step.n, { x: bx, y: by, w: 0.55, h: 0.55, fontSize: 16, bold: true, color: C.navy, fontFace: FONT, align: "center", valign: "middle", margin: 0 });
    s.addShape(pres.shapes.RECTANGLE, { x: 0.9, y: by, w: 1.6, h: 0.55, fill: { color: C.teal }, line: { color: C.teal } });
    s.addText(step.label, { x: 0.9, y: by, w: 1.6, h: 0.55, fontSize: 10.5, bold: true, color: C.white, fontFace: FONT, align: "center", valign: "middle", margin: 0 });
    s.addText(step.detail, { x: 2.55, y: by, w: 7.15, h: 0.55, fontSize: 10, color: C.offWhite, fontFace: FONT, valign: "middle" });
  });
  addFooter(s, "Viral Hepatitis – Internal Medicine Grand Rounds");
}

// ═══════════════════════════════════════════════
// SLIDE 20 – SUMMARY & KEY TAKEAWAYS
// ═══════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkSlide(s);
  addHeader(s, "Key Takeaways");

  const pts = [
    ["HAV & HEV:", "Fecal-oral, self-limited; no chronic infection in immunocompetent — but HEV in 3rd trimester pregnancy = 20% mortality"],
    ["HBV:", "300M carriers; perinatal → 90% chronic; treat with TDF or ETV (high resistance barrier); vaccine prevents HBV AND HDV"],
    ["HCV:", "80–90% chronicity; now CURABLE >95% with 8–12 weeks of DAA therapy; no vaccine; screen everyone 18–79"],
    ["HDV:", "Defective virus requiring HBV; superinfection = worst prognosis (cirrhosis 70–80%); HBV vaccination is the ultimate prevention"],
    ["HEV:", "Self-limited in immunocompetent; chronic in immunosuppressed (ribavirin); devastating in pregnancy"],
    ["Complications:", "Fulminant failure → transplant emergency (Status 1, list in 24h); Cirrhosis; HCC → ultrasound ± AFP q6 months surveillance"],
    ["Screen:", "CDC: universal HCV testing ages 18–79; HBsAg in high-risk groups; screen for HBV before starting HCV DAAs"],
  ];

  const textArr = [];
  pts.forEach(([label, text], i) => {
    textArr.push({ text: label + "  ", options: { bold: true, color: C.gold, fontSize: 13, fontFace: FONT } });
    textArr.push({ text, options: { color: C.offWhite, fontSize: 13, fontFace: FONT, breakLine: i < pts.length - 1, paraSpaceAfter: 4 } });
  });
  s.addText(textArr, { x: 0.4, y: bodyY(), w: 9.2, h: bodyH(), valign: "top" });
  addFooter(s, "Viral Hepatitis – Internal Medicine Grand Rounds  |  Sources: Robbins & Kumar, Katzung, Yamada's, Goldman-Cecil, Sleisenger & Fordtran's");
}

// ─────────────────────────────────────────────
// WRITE FILE
// ─────────────────────────────────────────────
pres.writeFile({ fileName: "/home/daytona/workspace/viral-hepatitis-ppt/ViralHepatitis_InternalMedicine.pptx" })
  .then(() => console.log("✅ Saved: /home/daytona/workspace/viral-hepatitis-ppt/ViralHepatitis_InternalMedicine.pptx"))
  .catch(e => console.error("❌ Error:", e));

Your credits are exhausted. Your daily credits reset tomorrow, or you can purchase a top-up for more.

I meant give me the JavaScript to run to generate a ppt

Your credits are exhausted. Your daily credits reset tomorrow, or you can purchase a top-up for more.

This is a shared conversation. Sign in to Orris to start your own chat.